Theralase Technologies Inc. V.TLT

RE:RE:RE:RE:RE:Just asking for numbers.

[CancerSlayer]

DJDawg wrote:
IBRX doesn't seem to be selling much anktiva based on last financials. So you could argue that urologists are saying that that medication doesn't meet their needs. Plus anktiva needs BCG which is in short supply to start with.

Adstiladrin is made by private company with no financials out. So hard to guess the sales. But I doubt that they are that great judging but DOR for the drug.

So, there is an unmet need in reality but perhaps not on paper.

Good points...
In a nutshell, you enhance the care of patients by utilizing agreed upon treatments (i.e. data-driven acceptance by the IBCG, AUA, EUA) that are  not only evidence-based, but can also be "practically" used in the outpatient care setting.  The latter requires that your option be simple, cost-effective, fit into/complement current workflows, & be "both" patient & provider-friendly.  Our ACT fills that bill.

Imo, current treatment options have difficulty in satisfactorily meeting all of the above points.  Success is ultimately going to boil down to "reality" as you stated, which will be heavily dependent on updated recommendations made by a respected body of experts (i.e. IBCG/International Bladder Cancer Group) & provider acceptance en masse.  Any complex treatment option/guideline that requires an in-depth review of a complex app for every visit, a higher patient/doctor burden (i.e. more frequent treatments/side effects) & prohibitive $ cost isn't going to have sustainability.  

Practicality & Simplicity should play key roles in our future success.  Anything  less is seldom used or eventually forgotten.  Good luck...